# Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects

> **NCT01596712** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 209 (actual)

## Conditions studied

- Allergy

## Interventions

- **DRUG:** QGE031
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01596712
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2012-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01596712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01596712, "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01596712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*